Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor
Overview
General Medicine
Authors
Affiliations
Background: Recently, modification of T cells with chimeric antigen receptor (CAR) has been an attractive approach for adoptive immunotherapy of cancers. Typically, CARs contain a single-chain variable domain fragment (scFv). Most often, scfvs are derived from a monoclonal antibody of murine origin and may be a trigger for host immune system that leads to the T-cell clearance. Nanobody is a specific antigen-binding fragment derived from camelid that has great homology to human VH and low immunogenic potential. Therefore, in this study, nanobody was employed instead of scFv in CAR construct.
Methods: In this study, a CAR was constructed based on a nanobody against PSMA (NBPII-CAR). At first, Jurkat cells were electroporated with NBPII-CAR, and then flow cytometry was performed for NBPII-CAR expression. For functional analysis, CAR T cells were co-cultured with prostate cancer cells and analyzed for IL-2 secretion, CD25 expression, and cell proliferation.
Results: Flow cytometry results confirmed the expression of NBPII-CAR on the transfected Jurkat cells. Our data showed the specificity of engineered Jurkat cells against prostate cancer cells by not only increasing the IL-2 cytokine (about 370 pg/ml) but also expressing the T-cell activation marker CD25 (about 30%). In addition, proliferation of engineered Jurkat cells increased nearly 60% when co-cultured with LNCaP (PSMA+), as compared with DU145 (PSMA-).
Conclusion: Here, we describe the ability of nanobody-based CAR to recognize PSMA that leads to the activation of Jurkat cells. This construct might be used as a promising candidate for clinical applications in prostate cancer therapy.
Guo S, Xi X Biomark Res. 2025; 13(1):41.
PMID: 40069884 PMC: 11899093. DOI: 10.1186/s40364-025-00755-5.
Jahan F, Koski J, Schenkwein D, Yla-Herttuala S, Goos H, Huuskonen S Front Mol Med. 2024; 3:1070384.
PMID: 39086686 PMC: 11285682. DOI: 10.3389/fmmed.2023.1070384.
Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell.
Taheri F, Hassani M, Sharifzadeh Z, Behdani M, Abdoli S, Sayadi M BMC Biotechnol. 2024; 24(1):1.
PMID: 38178096 PMC: 10768260. DOI: 10.1186/s12896-023-00827-0.
He M, Cao Y, Chi C, Zhao J, Chong E, Chin K Front Immunol. 2023; 14:1265751.
PMID: 37795091 PMC: 10545965. DOI: 10.3389/fimmu.2023.1265751.
Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells.
Hojjatipour T, Sharifzadeh Z, Maali A, Azad M Hum Cell. 2023; 36(6):1843-1864.
PMID: 37477869 DOI: 10.1007/s13577-023-00948-w.